CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of endometrial cancer.
  
  LEARNING OBJECTIVES

  • Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment for patients with endometrial cancer, and adapt current testing practices to effectively identify individuals with these genetic abnormalities.
  • Appreciate available and emerging research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer, and consider the current and potential role of this novel strategy in the care of patients with MSI-high/MMR-deficient or microsatellite stable/MMR-proficient disease.
  • Review the benefits observed with anti-PD-1/PD-L1 antibodies as monotherapy for MSI-high/MMR-deficient endometrial cancer, and appropriately integrate these agents into the care of patients with relapsed/refractory disease.
  • Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic endometrial cancer for this novel therapeutic approach.
  • Understand the biological rationale for and available and emerging data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for advanced or metastatic endometrial cancer.
  • Evaluate published clinical research documenting the efficacy of HER2-targeted agents and regimens in patients with HER2-overexpressing endometrial cancer, and consider the role of various approaches in disease management.
  • Describe the scientific justification for, published research data with and current studies evaluating novel agents and strategies for endometrial cancer, and effectively prioritize clinical trial opportunities for eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/SGO24Endometrial/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Nicoletta Colombo, MD
  Director, Gynecologic Oncology Program
  European Institute of Oncology IRCCS
  University of Milano-Bicocca
  Milan, Italy
  
  Advisory Committees: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, MSD, Novocure Inc, Nuvation Bio, OncXerna Therapeutics Inc, Pieris Pharmaceuticals Inc, Roche Laboratories Inc; Consulting Agreements: MSD, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, GSK; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GSK, Merck, MSD.
  
  Matthew A Powell, MD
  Professor, Department of Obstetrics and Gynecology
  Washington University School of Medicine
  St Louis, Missouri
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, ImmunoGen Inc, Merck, Seagen Inc.
  
  Brian M Slomovitz, MD
  Professor, OB-GYN, Florida International University
  Director, Gynecologic Oncology
  Co-Chair, Cancer Research Committee
  Mount Sinai Medical Center
  Miami, Florida
  
  Consulting Agreements: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, ImmunoGen Inc, Merck, Novocure Inc; Speakers Bureau: Seagen Inc; Nonrelevant Financial Relationship: GOG Foundation Inc.
  
  VIDEO PARTICIPANTS — Floor J Backes, MD — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, BioNTech SE, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, GSK, ImmunoGen Inc, Merck. Ritu Salani, MD, MBA — Advisory Committees: Eisai Inc, GSK, ImmunoGen Inc, Merck, Regeneron Pharmaceuticals Inc, Seagen Inc.
  
  MODERATOR
  Shannon N Westin, MD, MPH, FASCO, FACOG
  Professor
  Medical Director, Gynecologic Oncology Center
  Director, Early Drug Development
  Department of Gynecologic Oncology and Reproductive Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Clovis Oncology, Eisai Inc, EQRx, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK,Immunocore, ImmunoGen Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Biopharmaceuticals, Nuvectis Pharma Inc, pharmaand GmbH, Seagen Inc, Verastem Inc, Vincerx Pharma, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings, Clovis Oncology, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, pharmaand GmbH, Zentalis Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Karyopharm Therapeutics.
  
  Release date: April 2024
  Expiration date: April 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.